INTRAVITREOUS AND PLASMA-CONCENTRATIONS OF GANCICLOVIR AND FOSCARNET AFTER INTRAVENOUS THERAPY IN PATIENTS WITH AIDS AND CYTOMEGALOVIRUS RETINITIS

被引:67
作者
AREVALO, JF
GONZALEZ, C
CAPPARELLI, EV
KIRSCH, LS
GARCIA, RP
QUICENO, JI
CONNOR, JD
GAMBERTOGLIO, J
BERGERONLYNN, G
FREEMAN, WR
机构
[1] UNIV CALIF SAN DIEGO,SHILEY EYE CTR 0946,DEPT OPHTHALMOL,LA JOLLA,CA 92093
[2] UNIV CALIF SAN DIEGO,DEPT PEDIAT,LA JOLLA,CA 92093
[3] UNIV CALIF SAN DIEGO,DEPT PHARM,LA JOLLA,CA 92093
[4] UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143
关键词
D O I
10.1093/infdis/172.4.951
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study evaluated intravitreous and plasma ganciclovir and foscarnet concentrations after intravenous administration in AIDS patients with cytomegalovirus (CMV) retinitis and retinal detachment, Undiluted vitreous samples were prospectively obtained from 60 eyes (52 patients) at the time of pars plana vitrectomy, Thirty-three plasma samples (from 27 patients in the initial group of 52) were obtained simultaneously during surgery on 33 eyes. High-pressure liquid chromatography showed the mean vitreous ganciclovir concentrations in patients on induction and maintenance therapy were, respectively, 4.74 +/- 1.49 mu M (n = 24) and 3.29 +/- 1.84 mu M (n = 30; P = .005). Simultaneous plasma ganciclovir concentrations were less than the vitreous concentrations in 78% of the patients. The mean intravitreous foscarnet concentrations in patients receiving induction dosages were 189 +/- 177 mu M (n = 5) versus 163 +/- 167 mu M (n = 4; P > .20) for those receiving maintenance therapy, The foscarnet vitreous plasma concentration ratio averaged 1.43, Current drugs and doses for CMV retinitis result in borderline or progressively subtherapeutic concentrations.
引用
收藏
页码:951 / 956
页数:6
相关论文
共 33 条
  • [1] INTRAOCULAR PENETRATION OF CEFAZOLIN SODIUM IN RABBITS
    ABEL, R
    BOYLE, GL
    FURMAN, M
    LEOPOLD, IH
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1974, 78 (05) : 779 - 787
  • [2] BARZA M, 1983, INVEST OPHTH VIS SCI, V24, P1602
  • [3] BENNUN J, 1989, INVEST OPHTH VIS SCI, V30, P1055
  • [4] A HUMAN CYTOMEGALOVIRUS MUTANT RESISTANT TO THE NUCLEOSIDE ANALOG 9-([2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY]METHYL)GUANINE (BW B759U) INDUCES REDUCED LEVELS OF BW B759U TRIPHOSPHATE
    BIRON, KK
    FYFE, JA
    STANAT, SC
    LESLIE, LK
    SORRELL, JB
    LAMBE, CU
    COEN, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (22) : 8769 - 8773
  • [5] THE OCULAR PENETRATION OF ORAL SPARFLOXACIN IN HUMANS
    BRON, AM
    PECHINOT, AP
    GARCHER, CP
    GUYONNET, GA
    KAZMIERCZAK, A
    SCHOTT, DA
    LECOEUR, H
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 117 (03) : 322 - 327
  • [6] THE CLEARANCE OF INTRAVITREAL GENTAMICIN
    COBO, LM
    FORSTER, RK
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1981, 92 (01) : 59 - 62
  • [7] INVITRO SUSCEPTIBILITY OF CYTOMEGALOVIRUS ISOLATES FROM IMMUNOCOMPROMISED PATIENTS TO ACYCLOVIR AND GANCICLOVIR
    COLE, NL
    BALFOUR, HH
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1987, 6 (03) : 255 - 261
  • [8] PREVALENCE OF RESISTANCE IN PATIENTS RECEIVING GANCICLOVIR FOR SERIOUS CYTOMEGALOVIRUS-INFECTION
    DREW, WL
    MINER, RC
    BUSCH, DF
    FOLLANSBEE, SE
    GULLETT, J
    MEHALKO, SG
    GORDON, SM
    OWEN, WF
    MATTHEWS, TR
    BUHLES, WC
    DEARMOND, B
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) : 716 - 719
  • [9] TREATMENT OF CYTOMEGALO-VIRUS RETINITIS WITH 9-[2-HYDROXY-1-(HYDROXYMETHYL)ETHOXYMETHYL]GUANINE
    FELSENSTEIN, D
    DAMICO, DJ
    HIRSCH, MS
    NEUMEYER, DA
    CEDERBERG, DM
    DEMIRANDA, P
    SCHOOLEY, RT
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (03) : 377 - 380
  • [10] HUMAN PHARMACOKINETICS OF THE ANTIVIRAL DRUG DHPG
    FLETCHER, C
    SAWCHUK, R
    CHINNOCK, B
    DEMIRANDA, P
    BALFOUR, HH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (03) : 281 - 286